NEJM publishes PRIMAvera results showing restored central vision in geographic atrophy

Science Corporation/PRIMA retinal implant

NEJM published results from the PRIMAvera trial of PRIMA, a light-powered subretinal chip paired with camera glasses that restored functional central vision in geographic atrophy patients. Eighty per cent of patients achieved meaningful gains in visual acuity and could read letters, numbers and words; the mean improvement was 25.5 letters on the visual acuity chart.

• PRIMA uses light-powered subretinal array; 80% of patients gained meaningful visual acuity improvements.
• 84% could read letters, numbers and words; mean gain of 25.5 letters (5+ lines on eye chart).
• No significant decline in peripheral natural vision observed in 38 patients across 17 sites in five countries.